loader image
Sunday, November 23, 2025
74.4 F
McAllen
- Advertisement -

Urging caution on AI in mammography

Translate to Spanish or other 102 languages!

Doctors should proceed cautiously, because similar technological leaps previously led to higher rates of false-positive tests and over-treatment. Newswise Image
Doctors should proceed cautiously, because similar technological leaps previously led to higher rates of false-positive tests and over-treatment. Newswise Image

Mega Doctor News

- Advertisement -

 By University of California, Los Angeles (UCLA), Health Sciences 

Newswise — Analyzing breast-cancer tumors with artificial intelligence has the potential to improve healthcare efficiency and outcomes. But doctors should proceed cautiously, because similar technological leaps previously led to higher rates of false-positive tests and over-treatment.

That’s according to a new editorial in JAMA Health Forum co-written by Joann G. Elmore, MD, MPH, a researcher at the UCLA Jonsson Comprehensive Cancer Center, the Rosalinde and Arthur Gilbert Foundation Endowed Chair in Health Care Delivery and professor of medicine at the David Geffen School of Medicine at UCLA.

- Advertisement -

“Without a more robust approach to the evaluation and implementation of AI, given the unabated adoption of emergent technology in clinical practice, we are failing to learn from our past mistakes in mammography,” the JAMA Health Forum editorial states. The piece, posted online Friday, was co-written with Christoph I. Lee, MD, MS, MBA, a professor of radiology at the University of Washington School of Medicine.

One of those “past mistakes in mammography,” according to the authors, was adjunct computer-aided detection (CAD) tools, which grew rapidly in popularity in the field of breast cancer screening starting more than two decades ago. CAD was approved by the FDA in 1998, and by 2016 more than 92% of U.S. imaging facilities were using the technology to interpret mammograms and hunt for tumors. But the evidence showed CAD did not improve mammography accuracy. “CAD tools are associated with increased false positive rates, leading to overdiagnosis of ductal carcinoma in situ and unnecessary diagnostic testing,” the authors wrote. Medicare stopped paying for CAD in 2018, but by then the tools had racked up more than $400 million a year in unnecessary health costs.

“The premature adoption of CAD is a premonitory symptom of the wholehearted embrace of emergent technologies prior to fully understanding their impact on patient outcomes,” Elmore and Lee wrote.

The doctors suggest several safeguards to put in place to avoid “repeating past mistakes,” including tying Medicare reimbursement to “improved patient outcomes, not just improved technical performance in artificial settings.”

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Current Heart Attack Screening Tools Are Not Optimal and Fail to Identify Half the People Who Are at Risk

Current cardiac screening tools used to prevent heart attacks fail to identify nearly half of the people who are actually at risk of having one, according to a new study led by Mount Sinai researchers.

Don’t Overfill Your Plate or Stomach

We’ve all been there: You’re gathered with family or friends for a delicious holiday meal. You start piling food on your plate, and before you know it, there’s no room left – and you haven’t even made it to the cranberry sauce and sweet potatoes.

UT Health San Antonio Center For Brain Health Celebrates with Ribbon Cutting

University of Texas System and UT San Antonio leaders today hailed “a new era of hope, healing and discovery” for neurological patients and their families with a ribbon-cutting for the UT Health San Antonio Center for Brain Health, a $100 million, 103,000-square-foot facility that will bring specialty care, therapy, diagnostics and research under one ro

Rare Mutation that Predicts Strong Immunotherapy Response in Colorectal Cancer Identified

A new study led by researchers at The University of Texas MD Anderson Cancer Center shows that a specific subset of mutations in the POLE gene is strongly associated with durable responses to immunotherapy in patients with metastatic colorectal cancer (CRC).
- Advertisement -
×